Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

Study First Received, September 29,2020
Lead Sponsor: Anavex Life Sciences Corp. (Funder Type: Industry)
Conditions
Parkinson Disease Dementia
Interventions
Drug: ANAVEX2-73
Study Type
Interventional
Phase
Phase 2
Status
ongoing, recruiting (120 patients)
Study Duration
2019-10-10 to 2021-10-31
Overview Outcomes Eligibility Locations Investigators No Results
Overview
Official Title
Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

Summary
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.

Detailed Description
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.

Arms
ANAVEX2-73 Active Experimental Oral capsules

Funder Type
Industry

Lead Sponsor
Anavex Life Sciences Corp.

Collaborators
Anavex Australia Pty Ltd. (Other), Anavex Germany GmbH (Other)

First Received
2020-09-29

Last Updated
2020-10-05

Start Date
2019-10-10

Primary Completion
2021-10-31

Completion Date
2021-10-31

NCT Identifie
NCT04575259

Outcomes
Eligibility
Locations
Investigators
No Results